{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:08:15Z","timestamp":1794892095735,"version":"4.9.1"},"reference-count":306,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Gene expression is finely controlled by the abundance and activation status of transcription factors and their regulators, as well as by a number of reversible modifications of DNA and histones that are commonly referred to as epigenetic marks. Such alterations (i.e., methylation, acetylation, and ubiquitination) are catalyzed by an array of dedicated enzymes with antagonistic activity, including methyltransferases and demethylases, acetyltransferases and deacetylases, as well as ubiquitin ligases and deubiquitinating enzymes. The epigenetic control of transcription is critical not only for embryonic and postembryonic development but also for the preservation of homeostasis in all adult tissues. In line with this notion, epigenetic defects have been associated with a variety of human disorders, including (but not limited to) congenital conditions as well as multiple hematological and solid tumors. Here, we provide an in-depth discussion of the impact of epigenetic alterations on cancer stemness, i.e., the ability of a small population of poorly differentiated malignant cells to (1) self-renew while generating a more differentiated progeny, and (2) exhibit superior tumor initiating\/repopulating potential along with exceptional plasticity and improved resistance to environmental and therapy-elicited stress. Moreover, we critically evaluate the potential and limitations of targeting epigenetic modifiers as a means to eradicate cancer stem cells for therapeutic purposes.<\/jats:p>","DOI":"10.1038\/s41392-025-02340-6","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T23:02:22Z","timestamp":1754002942000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Epigenetic regulation of cancer stemness"],"prefix":"10.1038","volume":"10","author":[{"given":"Claudia","family":"Galassi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenola","family":"Manic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"Esteller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Galluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5918-1841","authenticated-orcid":false,"given":"Ilio","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"2340_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41586-019-1517-4","volume":"573","author":"P Cramer","year":"2019","unstructured":"Cramer, P. Organization and regulation of gene transcription. Nature 573, 45\u201354 (2019).","journal-title":"Nature"},{"key":"2340_CR2","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41580-018-0028-8","volume":"19","author":"V Haberle","year":"2018","unstructured":"Haberle, V. & Stark, A. Eukaryotic core promoters and the functional basis of transcription initiation. Nat. Rev. Mol. Cell Biol. 19, 621\u2013637 (2018).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2340_CR3","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.cell.2018.01.029","volume":"172","author":"SA Lambert","year":"2018","unstructured":"Lambert, S. A. et al. The human transcription factors. Cell 172, 650\u2013665 (2018).","journal-title":"Cell"},{"key":"2340_CR4","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nrg.2016.59","volume":"17","author":"CD Allis","year":"2016","unstructured":"Allis, C. D. & Jenuwein, T. The molecular hallmarks of epigenetic control. Nat. Rev. Genet. 17, 487\u2013500 (2016).","journal-title":"Nat. Rev. Genet."},{"key":"2340_CR5","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41576-022-00468-7","volume":"23","author":"G Mill\u00e1n-Zambrano","year":"2022","unstructured":"Mill\u00e1n-Zambrano, G., Burton, A., Bannister, A. J. & Schneider, R. Histone post-translational modifications-cause and consequence of genome function. Nat. Rev. Genet. 23, 563\u2013580 (2022).","journal-title":"Nat. Rev. Genet."},{"key":"2340_CR6","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1056\/NEJMra1402513","volume":"378","author":"AP Feinberg","year":"2018","unstructured":"Feinberg, A. P. The key role of epigenetics in human disease prevention and mitigation. N. Engl. J. Med. 378, 1323\u20131334 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2340_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nrg3607","volume":"15","author":"T Chen","year":"2014","unstructured":"Chen, T. & Dent, S. Y. Chromatin modifiers and remodellers: regulators of cellular differentiation. Nat. Rev. Genet. 15, 93\u2013106 (2014).","journal-title":"Nat. Rev. Genet."},{"key":"2340_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1093\/ije\/dyr184","volume":"41","author":"CH Waddington","year":"2012","unstructured":"Waddington, C. H. The epigenotype. 1942. Int. J. Epidemiol. 41, 10\u201313 (2012).","journal-title":"Int. J. Epidemiol."},{"key":"2340_CR9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ceb.2020.12.014","volume":"69","author":"A Elsherbiny","year":"2021","unstructured":"Elsherbiny, A. & Dobreva, G. Epigenetic memory of cell fate commitment. Curr. Opin. Cell Biol. 69, 80\u201387 (2021).","journal-title":"Curr. Opin. Cell Biol."},{"key":"2340_CR10","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nrg.2017.57","volume":"18","author":"Y Atlasi","year":"2017","unstructured":"Atlasi, Y. & Stunnenberg, H. G. The interplay of epigenetic marks during stem cell differentiation and development. Nat. Rev. Genet. 18, 643\u2013658 (2017).","journal-title":"Nat. Rev. Genet."},{"key":"2340_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31\u201346 (2022).","journal-title":"Cancer Discov."},{"key":"2340_CR12","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1158\/2159-8290.CD-24-0296","volume":"14","author":"M Esteller","year":"2024","unstructured":"Esteller, M. et al. The epigenetic hallmarks of cancer. Cancer Discov. 14, 1783\u20131809 (2024).","journal-title":"Cancer Discov."},{"key":"2340_CR13","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd4360","volume":"13","author":"KJ Falkenberg","year":"2014","unstructured":"Falkenberg, K. J. & Johnstone, R. W. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat. Rev. Drug Discov. 13, 673\u2013691 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2340_CR14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nrclinonc.2010.87","volume":"7","author":"A Quint\u00e1s-Cardama","year":"2010","unstructured":"Quint\u00e1s-Cardama, A., Santos, F. P. & Garcia-Manero, G. Therapy with azanucleosides for myelodysplastic syndromes. Nat. Rev. Clin. Oncol. 7, 433\u2013444 (2010).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2340_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.stem.2018.12.009","volume":"24","author":"BC Prager","year":"2019","unstructured":"Prager, B. C., Xie, Q., Bao, S. & Rich, J. N. Cancer stem cells: the architects of the tumor ecosystem. Cell Stem Cell 24, 41\u201353 (2019).","journal-title":"Cell Stem Cell"},{"key":"2340_CR16","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/nm.4409","volume":"23","author":"E Batlle","year":"2017","unstructured":"Batlle, E. & Clevers, H. Cancer stem cells revisited. Nat. Med. 23, 1124\u20131134 (2017).","journal-title":"Nat. Med."},{"key":"2340_CR17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.stem.2024.04.004","volume":"31","author":"JJ Loh","year":"2024","unstructured":"Loh, J. J. & Ma, S. Hallmarks of cancer stemness. Cell Stem Cell 31, 617\u2013639 (2024).","journal-title":"Cell Stem Cell"},{"key":"2340_CR18","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.trecan.2024.08.004","volume":"10","author":"C Galassi","year":"2024","unstructured":"Galassi, C., Esteller, M., Vitale, I. & Galluzzi, L. Epigenetic control of immunoevasion in cancer stem cells. Trends Cancer 10, 1052\u20131071 (2024).","journal-title":"Trends Cancer"},{"key":"2340_CR19","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ccell.2024.09.010","volume":"42","author":"C Galassi","year":"2024","unstructured":"Galassi, C., Chan, T. A., Vitale, I. & Galluzzi, L. The hallmarks of cancer immune evasion. Cancer Cell 42, 1825\u20131863 (2024).","journal-title":"Cancer Cell"},{"key":"2340_CR20","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1158\/0008-5472.CAN-17-1724","volume":"78","author":"AW Hall","year":"2018","unstructured":"Hall, A. W. et al. Bivalent chromatin domains in glioblastoma reveal a subtype-specific signature of glioma stem cells. Cancer Res. 78, 2463\u20132474 (2018).","journal-title":"Cancer Res."},{"key":"2340_CR21","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1101\/gr.131169.111","volume":"22","author":"H Easwaran","year":"2012","unstructured":"Easwaran, H. et al. A DNA hypermethylation module for the stem\/progenitor cell signature of cancer. Genome Res. 22, 837\u2013849 (2012).","journal-title":"Genome Res."},{"key":"2340_CR22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.stem.2008.11.015","volume":"4","author":"TC Somervaille","year":"2009","unstructured":"Somervaille, T. C. et al. Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell 4, 129\u2013140 (2009).","journal-title":"Cell Stem Cell"},{"key":"2340_CR23","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/ng.127","volume":"40","author":"I Ben-Porath","year":"2008","unstructured":"Ben-Porath, I. et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet 40, 499\u2013507 (2008).","journal-title":"Nat. Genet"},{"key":"2340_CR24","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.trecan.2017.04.004","volume":"3","author":"EN Wainwright","year":"2017","unstructured":"Wainwright, E. N. & Scaffidi, P. Epigenetics and cancer stem cells: unleashing, hijacking, and restricting cellular plasticity. Trends Cancer 3, 372\u2013386 (2017).","journal-title":"Trends Cancer"},{"key":"2340_CR25","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41392-024-01851-y","volume":"9","author":"X Chu","year":"2024","unstructured":"Chu, X. et al. Cancer stem cells: advances in knowledge and implications for cancer therapy. Signal Transduct. Target Ther. 9, 170 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2340_CR26","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jgg.2015.06.003","volume":"42","author":"EJ Lee","year":"2015","unstructured":"Lee, E. J. et al. Identification of global DNA methylation signatures in glioblastoma-derived cancer stem cells. J. Genet Genom. 42, 355\u2013371 (2015).","journal-title":"J. Genet Genom."},{"key":"2340_CR27","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1002\/stem.1792","volume":"32","author":"R El Helou","year":"2014","unstructured":"El Helou, R. et al. Brief reports: a distinct DNA methylation signature defines breast cancer stem cells and predicts cancer outcome. Stem Cells 32, 3031\u20133036 (2014).","journal-title":"Stem Cells"},{"key":"2340_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7910","volume":"6","author":"R Pathania","year":"2015","unstructured":"Pathania, R. et al. DNMT1 is essential for mammary and cancer stem cell maintenance and tumorigenesis. Nat. Commun. 6, 6910 (2015).","journal-title":"Nat. Commun."},{"key":"2340_CR29","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1101\/gad.184341.111","volume":"26","author":"JJ Trowbridge","year":"2012","unstructured":"Trowbridge, J. J. et al. Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains. Genes Dev. 26, 344\u2013349 (2012).","journal-title":"Genes Dev."},{"key":"2340_CR30","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41418-019-0389-3","volume":"27","author":"H Liu","year":"2020","unstructured":"Liu, H. et al. Downregulation of FOXO3a by DNMT1 promotes breast cancer stem cell properties and tumorigenesis. Cell Death Differ. 27, 966\u2013983 (2020).","journal-title":"Cell Death Differ."},{"key":"2340_CR31","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.yexmp.2012.10.004","volume":"94","author":"R Morita","year":"2013","unstructured":"Morita, R. et al. DNA methyltransferase 1 is essential for initiation of the colon cancers. Exp. Mol. Pathol. 94, 322\u2013329 (2013).","journal-title":"Exp. Mol. Pathol."},{"key":"2340_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202202216","volume":"9","author":"Y Wei","year":"2022","unstructured":"Wei, Y. et al. The interaction between DNMT1 and high-mannose CD133 maintains the slow-cycling state and tumorigenic potential of glioma stem cell. Adv. Sci. 9, e2202216 (2022).","journal-title":"Adv. Sci."},{"key":"2340_CR33","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/s41418-023-01153-w","volume":"30","author":"I Vitale","year":"2023","unstructured":"Vitale, I. et al. Apoptotic cell death in disease-current understanding of the NCCD 2023. Cell Death Differ. 30, 1097\u20131154 (2023).","journal-title":"Cell Death Differ."},{"key":"2340_CR34","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.jhep.2021.06.025","volume":"75","author":"Q Wang","year":"2021","unstructured":"Wang, Q. et al. DNMT1-mediated methylation of BEX1 regulates stemness and tumorigenicity in liver cancer. J. Hepatol. 75, 1142\u20131153 (2021).","journal-title":"J. Hepatol."},{"key":"2340_CR35","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1158\/0008-5472.CAN-19-2104","volume":"80","author":"M Bruschi","year":"2020","unstructured":"Bruschi, M. et al. Loss of Apc rapidly impairs DNA methylation programs and cell fate decisions in Lgr5(+) intestinal stem cells. Cancer Res. 80, 2101\u20132113 (2020).","journal-title":"Cancer Res."},{"key":"2340_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41392-021-00857-0","volume":"7","author":"H Lopez-Bertoni","year":"2022","unstructured":"Lopez-Bertoni, H. et al. Sox2 induces glioblastoma cell stemness and tumor propagation by repressing TET2 and deregulating 5hmC and 5mC DNA modifications. Signal Transduct. Target Ther. 7, 37 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"2340_CR37","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.cell.2018.11.046","volume":"176","author":"S Gkountela","year":"2019","unstructured":"Gkountela, S. et al. Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. Cell 176, 98\u2013112.e114 (2019).","journal-title":"Cell"},{"key":"2340_CR38","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/leu.2011.326","volume":"26","author":"S Weissmann","year":"2012","unstructured":"Weissmann, S. et al. Landscape of TET2 mutations in acute myeloid leukemia. Leukemia 26, 934\u2013942 (2012).","journal-title":"Leukemia"},{"key":"2340_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26093-2","volume":"12","author":"M Tulstrup","year":"2021","unstructured":"Tulstrup, M. et al. TET2 mutations are associated with hypermethylation at key regulatory enhancers in normal and malignant hematopoiesis. Nat. Commun. 12, 6061 (2021).","journal-title":"Nat. Commun."},{"key":"2340_CR40","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ccell.2015.03.009","volume":"27","author":"AH Shih","year":"2015","unstructured":"Shih, A. H. et al. Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. Cancer Cell 27, 502\u2013515 (2015).","journal-title":"Cancer Cell"},{"key":"2340_CR41","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.3324\/haematol.2013.088740","volume":"98","author":"F Asmar","year":"2013","unstructured":"Asmar, F. et al. Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma. Haematologica 98, 1912\u20131920 (2013).","journal-title":"Haematologica"},{"key":"2340_CR42","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1038\/s41556-024-01496-7","volume":"26","author":"L Guo","year":"2024","unstructured":"Guo, L. et al. Perturbing TET2 condensation promotes aberrant genome-wide DNA methylation and curtails leukaemia cell growth. Nat. Cell Biol. 26, 2154\u20132167 (2024).","journal-title":"Nat. Cell Biol."},{"key":"2340_CR43","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.cell.2017.07.032","volume":"170","author":"L Cimmino","year":"2017","unstructured":"Cimmino, L. et al. Restoration of TET2 function blocks aberrant self-renewal and leukemia progression. Cell 170, 1079\u20131095 e1020 (2017).","journal-title":"Cell"},{"key":"2340_CR44","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.stem.2023.07.001","volume":"30","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. TET2-mediated mRNA demethylation regulates leukemia stem cell homing and self-renewal. Cell Stem Cell 30, 1072\u20131090.e1010 (2023).","journal-title":"Cell Stem Cell"},{"key":"2340_CR45","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature24294","volume":"551","author":"S Raffel","year":"2017","unstructured":"Raffel, S. et al. BCAT1 restricts \u03b1KG levels in AML stem cells leading to IDHmut-like DNA hypermethylation. Nature 551, 384\u2013388 (2017).","journal-title":"Nature"},{"key":"2340_CR46","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","volume":"18","author":"CJ Pirozzi","year":"2021","unstructured":"Pirozzi, C. J. & Yan, H. The implications of IDH mutations for cancer development and therapy. Nat. Rev. Clin. Oncol. 18, 645\u2013661 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2340_CR47","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","volume":"18","author":"ME Figueroa","year":"2010","unstructured":"Figueroa, M. E. et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553\u2013567 (2010).","journal-title":"Cancer Cell"},{"key":"2340_CR48","first-page":"270","volume":"52","author":"Q Yao","year":"2018","unstructured":"Yao, Q. et al. IDH1 mutation diminishes aggressive phenotype in glioma stem cells. Int J. Oncol. 52, 270\u2013278 (2018).","journal-title":"Int J. Oncol."},{"key":"2340_CR49","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/1878-0261.13051","volume":"16","author":"R Tanabe","year":"2022","unstructured":"Tanabe, R. et al. PRRX1 induced by BMP signaling decreases tumorigenesis by epigenetically regulating glioma-initiating cell properties via DNA methyltransferase 3A. Mol. Oncol. 16, 269\u2013288 (2022).","journal-title":"Mol. Oncol."},{"key":"2340_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-021-02352-9","volume":"22","author":"H Kim","year":"2021","unstructured":"Kim, H. et al. Ten-eleven translocation protein 1 modulates medulloblastoma progression. Genome Biol. 22, 125 (2021).","journal-title":"Genome Biol."},{"key":"2340_CR51","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1002\/stem.2621","volume":"35","author":"P Prasad","year":"2017","unstructured":"Prasad, P. et al. Hypoxia-mediated epigenetic regulation of stemness in brain tumor cells. Stem Cells 35, 1468\u20131478 (2017).","journal-title":"Stem Cells"},{"key":"2340_CR52","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/ni.3148","volume":"16","author":"L Cimmino","year":"2015","unstructured":"Cimmino, L. et al. TET1 is a tumor suppressor of hematopoietic malignancy. Nat. Immunol. 16, 653\u2013662 (2015).","journal-title":"Nat. Immunol."},{"key":"2340_CR53","doi-asserted-by":"publisher","first-page":"11994","DOI":"10.1073\/pnas.1310656110","volume":"110","author":"H Huang","year":"2013","unstructured":"Huang, H. et al. TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc. Natl. Acad. Sci. USA 110, 11994\u201311999 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2340_CR54","doi-asserted-by":"publisher","first-page":"eabq8513","DOI":"10.1126\/scitranslmed.abq8513","volume":"15","author":"Z Chen","year":"2023","unstructured":"Chen, Z. et al. Phosphorylation stabilized TET1 acts as an oncoprotein and therapeutic target in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 15, eabq8513 (2023).","journal-title":"Sci. Transl. Med."},{"key":"2340_CR55","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","volume":"363","author":"TJ Ley","year":"2010","unstructured":"Ley, T. J. et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 363, 2424\u20132433 (2010).","journal-title":"N. Engl. J. Med."},{"key":"2340_CR56","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ccell.2016.05.008","volume":"30","author":"R Lu","year":"2016","unstructured":"Lu, R. et al. Epigenetic perturbations by Arg882-mutated DNMT3A potentiate aberrant stem cell gene-expression program and acute leukemia development. Cancer Cell 30, 92\u2013107 (2016).","journal-title":"Cancer Cell"},{"key":"2340_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10924","volume":"7","author":"J Koya","year":"2016","unstructured":"Koya, J. et al. DNMT3A R882 mutants interact with polycomb proteins to block haematopoietic stem and leukaemic cell differentiation. Nat. Commun. 7, 10924 (2016).","journal-title":"Nat. Commun."},{"key":"2340_CR58","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1038\/onc.2015.359","volume":"35","author":"HJ Ferreira","year":"2016","unstructured":"Ferreira, H. J. et al. DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia. Oncogene 35, 3079\u20133082 (2016).","journal-title":"Oncogene"},{"key":"2340_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41297-4","volume":"14","author":"MA Mouti","year":"2023","unstructured":"Mouti, M. A. et al. KMT2A associates with PHF5A-PHF14-HMG20A-RAI1 subcomplex in pancreatic cancer stem cells and epigenetically regulates their characteristics. Nat. Commun. 14, 5685 (2023).","journal-title":"Nat. Commun."},{"key":"2340_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20222-z","volume":"11","author":"J Grinat","year":"2020","unstructured":"Grinat, J. et al. The epigenetic regulator Mll1 is required for Wnt-driven intestinal tumorigenesis and cancer stemness. Nat. Commun. 11, 6422 (2020).","journal-title":"Nat. Commun."},{"key":"2340_CR61","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41375-020-0808-y","volume":"35","author":"L Godfrey","year":"2021","unstructured":"Godfrey, L. et al. H3K79me2\/3 controls enhancer-promoter interactions and activation of the pan-cancer stem cell marker PROM1\/CD133 in MLL-AF4 leukemia cells. Leukemia 35, 90\u2013106 (2021).","journal-title":"Leukemia"},{"key":"2340_CR62","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.canlet.2018.05.003","volume":"430","author":"T Wang","year":"2018","unstructured":"Wang, T. et al. SMYD3 controls a Wnt-responsive epigenetic switch for ASCL2 activation and cancer stem cell maintenance. Cancer Lett. 430, 11\u201324 (2018).","journal-title":"Cancer Lett."},{"key":"2340_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1009250","volume":"17","author":"N Goveas","year":"2021","unstructured":"Goveas, N. et al. MLL1 is required for maintenance of intestinal stem cells. PLoS Genet. 17, e1009250 (2021).","journal-title":"PLoS Genet."},{"key":"2340_CR64","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41580-022-00518-2","volume":"24","author":"TA Macrae","year":"2023","unstructured":"Macrae, T. A., Fothergill-Robinson, J. & Ramalho-Santos, M. Regulation, functions and transmission of bivalent chromatin during mammalian development. Nat. Rev. Mol. Cell Biol. 24, 6\u201326 (2023).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2340_CR65","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1101\/gad.349803.122","volume":"37","author":"K Mitchell","year":"2023","unstructured":"Mitchell, K. et al. WDR5 represents a therapeutically exploitable target for cancer stem cells in glioblastoma. Genes Dev. 37, 86\u2013102 (2023).","journal-title":"Genes Dev."},{"key":"2340_CR66","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.stem.2016.12.001","volume":"20","author":"AG Alvarado","year":"2017","unstructured":"Alvarado, A. G. et al. Glioblastoma cancer stem cells evade innate immune suppression of self-renewal through reduced TLR4 expression. Cell Stem Cell 20, 450\u2013461 e454 (2017).","journal-title":"Cell Stem Cell"},{"key":"2340_CR67","doi-asserted-by":"publisher","first-page":"eabf3917","DOI":"10.1126\/scitranslmed.abf3917","volume":"14","author":"D Dixit","year":"2022","unstructured":"Dixit, D. et al. Glioblastoma stem cells reprogram chromatin in vivo to generate selective therapeutic dependencies on DPY30 and phosphodiesterases. Sci. Transl. Med. 14, eabf3917 (2022).","journal-title":"Sci. Transl. Med."},{"key":"2340_CR68","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1158\/0008-5472.CAN-11-3589","volume":"72","author":"AB Mak","year":"2012","unstructured":"Mak, A. B., Nixon, A. M. & Moffat, J. The mixed lineage leukemia (MLL) fusion-associated gene AF4 promotes CD133 transcription. Cancer Res 72, 1929\u20131934 (2012).","journal-title":"Cancer Res"},{"key":"2340_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38919-2","volume":"14","author":"A Nikolic","year":"2023","unstructured":"Nikolic, A. et al. macroH2A2 antagonizes epigenetic programs of stemness in glioblastoma. Nat. Commun. 14, 3062 (2023).","journal-title":"Nat. Commun."},{"key":"2340_CR70","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.ccell.2015.10.005","volume":"28","author":"M Gallo","year":"2015","unstructured":"Gallo, M. et al. MLL5 orchestrates a cancer self-renewal state by repressing the histone variant H3.3 and globally reorganizing chromatin. Cancer Cell 28, 715\u2013729 (2015).","journal-title":"Cancer Cell"},{"key":"2340_CR71","doi-asserted-by":"publisher","first-page":"1444923","DOI":"10.3389\/fimmu.2024.1444923","volume":"15","author":"Y Jiao","year":"2024","unstructured":"Jiao, Y. et al. The modification role and tumor association with a methyltransferase: KMT2C. Front. Immunol. 15, 1444923 (2024).","journal-title":"Front. Immunol."},{"key":"2340_CR72","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41556-022-01045-0","volume":"25","author":"J Cui","year":"2023","unstructured":"Cui, J. et al. MLL3 loss drives metastasis by promoting a hybrid epithelial-mesenchymal transition state. Nat. Cell Biol. 25, 145\u2013158 (2023).","journal-title":"Nat. Cell Biol."},{"key":"2340_CR73","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccr.2012.03.014","volume":"21","author":"WJ Harris","year":"2012","unstructured":"Harris, W. J. et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 21, 473\u2013487 (2012).","journal-title":"Cancer Cell"},{"key":"2340_CR74","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1182\/blood-2014-11-610907","volume":"125","author":"T Wada","year":"2015","unstructured":"Wada, T. et al. Overexpression of the shortest isoform of histone demethylase LSD1 primes hematopoietic stem cells for malignant transformation. Blood 125, 3731\u20133746 (2015).","journal-title":"Blood"},{"key":"2340_CR75","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1182\/blood.2019002548","volume":"136","author":"CL Carmichael","year":"2020","unstructured":"Carmichael, C. L. et al. The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1. Blood 136, 957\u2013973 (2020).","journal-title":"Blood"},{"key":"2340_CR76","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1038\/onc.2016.395","volume":"36","author":"GR Sareddy","year":"2017","unstructured":"Sareddy, G. R. et al. Novel KDM1A inhibitors induce differentiation and apoptosis of glioma stem cells via unfolded protein response pathway. Oncogene 36, 2423\u20132434 (2017).","journal-title":"Oncogene"},{"key":"2340_CR77","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/ncb3396","volume":"18","author":"A Zhou","year":"2016","unstructured":"Zhou, A. et al. Nuclear GSK3\u03b2 promotes tumorigenesis by phosphorylating KDM1A and inducing its deubiquitylation by USP22. Nat. Cell Biol. 18, 954\u2013966 (2016).","journal-title":"Nat. Cell Biol."},{"key":"2340_CR78","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1093\/neuonc\/noad018","volume":"25","author":"S Alejo","year":"2023","unstructured":"Alejo, S. et al. Lysine-specific histone demethylase 1A (KDM1A\/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma. Neuro. Oncol. 25, 1249\u20131261 (2023).","journal-title":"Neuro. Oncol."},{"key":"2340_CR79","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.7150\/thno.66142","volume":"12","author":"W Zhang","year":"2022","unstructured":"Zhang, W. et al. KDM1A promotes thyroid cancer progression and maintains stemness through the Wnt\/\u03b2-catenin signaling pathway. Theranostics 12, 1500\u20131517 (2022).","journal-title":"Theranostics"},{"key":"2340_CR80","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.1038\/onc.2015.129","volume":"34","author":"ZJ Lei","year":"2015","unstructured":"Lei, Z. J. et al. Lysine-specific demethylase 1 promotes the stemness and chemoresistance of Lgr5(+) liver cancer initiating cells by suppressing negative regulators of \u03b2-catenin signaling. Oncogene 34, 3188\u20133198 (2015).","journal-title":"Oncogene"},{"key":"2340_CR81","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.celrep.2013.08.030","volume":"5","author":"Y Wu","year":"2013","unstructured":"Wu, Y. et al. The deubiquitinase USP28 stabilizes LSD1 and confers stem-cell-like traits to breast cancer cells. Cell Rep. 5, 224\u2013236 (2013).","journal-title":"Cell Rep."},{"key":"2340_CR82","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41375-023-01810-6","volume":"37","author":"ML Trempenau","year":"2023","unstructured":"Trempenau, M. L. et al. The histone demethylase KDM5C functions as a tumor suppressor in AML by repression of bivalently marked immature genes. Leukemia 37, 593\u2013605 (2023).","journal-title":"Leukemia"},{"key":"2340_CR83","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2122940119","volume":"119","author":"Z Ren","year":"2022","unstructured":"Ren, Z. et al. A PRC2-Kdm5b axis sustains tumorigenicity of acute myeloid leukemia. Proc. Natl. Acad. Sci. USA 119, e2122940119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2340_CR84","doi-asserted-by":"publisher","first-page":"7239","DOI":"10.1038\/s41388-020-01495-6","volume":"39","author":"Y Chu","year":"2020","unstructured":"Chu, Y. et al. SUV39H1 regulates the progression of MLL-AF9-induced acute myeloid leukemia. Oncogene 39, 7239\u20137252 (2020).","journal-title":"Oncogene"},{"key":"2340_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5619","volume":"5","author":"Y Tan","year":"2014","unstructured":"Tan, Y. et al. Matrix softness regulates plasticity of tumour-repopulating cells via H3K9 demethylation and Sox2 expression. Nat. Commun. 5, 4619 (2014).","journal-title":"Nat. Commun."},{"key":"2340_CR86","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1101\/gad.236794.113","volume":"28","author":"B Lehnertz","year":"2014","unstructured":"Lehnertz, B. et al. The methyltransferase G9a regulates HoxA9-dependent transcription in AML. Genes Dev. 28, 317\u2013327 (2014).","journal-title":"Genes Dev."},{"key":"2340_CR87","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1038\/s41388-021-01799-1","volume":"40","author":"M Zhou","year":"2021","unstructured":"Zhou, M. et al. Targeting protein lysine methyltransferase G9A impairs self-renewal of chronic myelogenous leukemia stem cells via upregulation of SOX6. Oncogene 40, 3564\u20133577 (2021).","journal-title":"Oncogene"},{"key":"2340_CR88","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/s41388-020-01591-7","volume":"40","author":"CJ Bergin","year":"2021","unstructured":"Bergin, C. J. et al. G9a controls pluripotent-like identity and tumor-initiating function in human colorectal cancer. Oncogene 40, 1191\u20131202 (2021).","journal-title":"Oncogene"},{"key":"2340_CR89","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1158\/2159-8290.CD-19-0532","volume":"10","author":"S Kato","year":"2020","unstructured":"Kato, S. et al. Gain-of-function genetic alterations of G9a drive oncogenesis. Cancer Discov. 10, 980\u2013997 (2020).","journal-title":"Cancer Discov."},{"key":"2340_CR90","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1016\/j.molcel.2022.11.010","volume":"82","author":"KW Fong","year":"2022","unstructured":"Fong, K. W. et al. PALI1 promotes tumor growth through competitive recruitment of PRC2 to G9A-target chromatin for dual epigenetic silencing. Mol. Cell 82, 4611\u20134626.e4617 (2022).","journal-title":"Mol. Cell"},{"key":"2340_CR91","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1038\/s41388-022-02417-4","volume":"41","author":"S Balinth","year":"2022","unstructured":"Balinth, S. et al. EZH2 regulates a SETDB1\/\u0394Np63\u03b1 axis via RUNX3 to drive a cancer stem cell phenotype in squamous cell carcinoma. Oncogene 41, 4130\u20134144 (2022).","journal-title":"Oncogene"},{"key":"2340_CR92","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/onc.2016.320","volume":"36","author":"S Ramadoss","year":"2017","unstructured":"Ramadoss, S. et al. Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance. Oncogene 36, 1537\u20131545 (2017).","journal-title":"Oncogene"},{"key":"2340_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15146","volume":"8","author":"J Li","year":"2017","unstructured":"Li, J. et al. KDM3 epigenetically controls tumorigenic potentials of human colorectal cancer stem cells through Wnt\/\u03b2-catenin signalling. Nat. Commun. 8, 15146 (2017).","journal-title":"Nat. Commun."},{"key":"2340_CR94","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1158\/0008-5472.CAN-19-1229","volume":"80","author":"Y Chen","year":"2020","unstructured":"Chen, Y. et al. Wnt-induced stabilization of KDM4C is required for Wnt\/\u03b2-Catenin target gene expression and glioblastoma tumorigenesis. Cancer Res. 80, 1049\u20131063 (2020).","journal-title":"Cancer Res."},{"key":"2340_CR95","doi-asserted-by":"publisher","first-page":"6095","DOI":"10.7150\/thno.44147","volume":"10","author":"TT Liao","year":"2020","unstructured":"Liao, T. T. et al. Harnessing stemness and PD-L1 expression by AT-rich interaction domain-containing protein 3B in colorectal cancer. Theranostics 10, 6095\u20136112 (2020).","journal-title":"Theranostics"},{"key":"2340_CR96","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1002\/ijc.32649","volume":"146","author":"JP Mallm","year":"2020","unstructured":"Mallm, J. P. et al. Glioblastoma initiating cells are sensitive to histone demethylase inhibition due to epigenetic deregulation. Int. J. Cancer 146, 1281\u20131292 (2020).","journal-title":"Int. J. Cancer"},{"key":"2340_CR97","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1172\/JCI82978","volume":"126","author":"N Zhu","year":"2016","unstructured":"Zhu, N. et al. MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C. J. Clin. Investig. 126, 997\u20131011 (2016).","journal-title":"J. Clin. Investig."},{"key":"2340_CR98","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.stem.2020.04.001","volume":"27","author":"J Wang","year":"2020","unstructured":"Wang, J. et al. Leukemogenic chromatin alterations promote AML leukemia stem cells via a KDM4C-ALKBH5-AXL signaling axis. Cell Stem Cell 27, 81\u201397.e88 (2020).","journal-title":"Cell Stem Cell"},{"key":"2340_CR99","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.stem.2020.04.009","volume":"27","author":"C Shen","year":"2020","unstructured":"Shen, C. et al. RNA demethylase ALKBH5 selectively promotes tumorigenesis and cancer stem cell self-renewal in acute myeloid leukemia. Cell Stem Cell 27, 64\u201380.e69 (2020).","journal-title":"Cell Stem Cell"},{"key":"2340_CR100","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1158\/2159-8290.CD-15-1439","volume":"6","author":"H Xie","year":"2016","unstructured":"Xie, H. et al. Chronic myelogenous leukemia-initiating cells require polycomb group protein EZH2. Cancer Discov. 6, 1237\u20131247 (2016).","journal-title":"Cancer Discov."},{"key":"2340_CR101","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1158\/2159-8290.CD-16-0263","volume":"6","author":"MT Scott","year":"2016","unstructured":"Scott, M. T. et al. Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition. Cancer Discov. 6, 1248\u20131257 (2016).","journal-title":"Cancer Discov."},{"key":"2340_CR102","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/s41580-021-00398-y","volume":"22","author":"NP Blackledge","year":"2021","unstructured":"Blackledge, N. P. & Klose, R. J. The molecular principles of gene regulation by polycomb repressive complexes. Nat. Rev. Mol. Cell Biol. 22, 815\u2013833 (2021).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2340_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09309-4","volume":"10","author":"E Lima-Fernandes","year":"2019","unstructured":"Lima-Fernandes, E. et al. Targeting bivalency de-represses Indian Hedgehog and inhibits self-renewal of colorectal cancer-initiating cells. Nat. Commun. 10, 1436 (2019).","journal-title":"Nat. Commun."},{"key":"2340_CR104","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/leu.2017.300","volume":"32","author":"S Fujita","year":"2018","unstructured":"Fujita, S. et al. Dual inhibition of EZH1\/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia. Leukemia 32, 855\u2013864 (2018).","journal-title":"Leukemia"},{"key":"2340_CR105","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.ccr.2013.04.008","volume":"23","author":"E Kim","year":"2013","unstructured":"Kim, E. et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 23, 839\u2013852 (2013).","journal-title":"Cancer Cell"},{"key":"2340_CR106","doi-asserted-by":"publisher","first-page":"9211","DOI":"10.1158\/0008-5472.CAN-09-1622","volume":"69","author":"ML Suv\u00e0","year":"2009","unstructured":"Suv\u00e0, M. L. et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res. 69, 9211\u20139218 (2009).","journal-title":"Cancer Res."},{"key":"2340_CR107","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ccr.2010.10.035","volume":"19","author":"CJ Chang","year":"2011","unstructured":"Chang, C. J. et al. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-\u03b2-catenin signaling. Cancer Cell 19, 86\u2013100 (2011).","journal-title":"Cancer Cell"},{"key":"2340_CR108","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.devcel.2024.03.020","volume":"59","author":"KA LaBella","year":"2024","unstructured":"LaBella, K. A. et al. Telomere dysfunction alters intestinal stem cell dynamics to promote cancer. Dev. Cell 59, 1475\u20131486.e1475 (2024).","journal-title":"Dev. Cell"},{"key":"2340_CR109","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1172\/JCI138577","volume":"130","author":"H Lu","year":"2020","unstructured":"Lu, H. et al. Chemotherapy-induced S100A10 recruits KDM6A to facilitate OCT4-mediated breast cancer stemness. J. Clin. Investig. 130, 4607\u20134623 (2020).","journal-title":"J. Clin. Investig."},{"key":"2340_CR110","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.7150\/thno.70581","volume":"12","author":"J Lan","year":"2022","unstructured":"Lan, J. et al. Chemotherapy-induced adenosine A2B receptor expression mediates epigenetic regulation of pluripotency factors and promotes breast cancer stemness. Theranostics 12, 2598\u20132612 (2022).","journal-title":"Theranostics"},{"key":"2340_CR111","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.stem.2016.11.003","volume":"20","author":"BB Liau","year":"2017","unstructured":"Liau, B. B. et al. Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance. Cell Stem Cell 20, 233\u2013246.e237 (2017).","journal-title":"Cell Stem Cell"},{"key":"2340_CR112","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3324\/haematol.2018.187708","volume":"103","author":"Y Zhou","year":"2018","unstructured":"Zhou, Y. et al. Setd2 regulates quiescence and differentiation of adult hematopoietic stem cells by restricting RNA polymerase II elongation. Haematologica 103, 1110\u20131123 (2018).","journal-title":"Haematologica"},{"key":"2340_CR113","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41422-018-0015-9","volume":"28","author":"YL Zhang","year":"2018","unstructured":"Zhang, Y. L. et al. Setd2 deficiency impairs hematopoietic stem cell self-renewal and causes malignant transformation. Cell Res. 28, 476\u2013490 (2018).","journal-title":"Cell Res."},{"key":"2340_CR114","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/ng.2894","volume":"46","author":"X Zhu","year":"2014","unstructured":"Zhu, X. et al. Identification of functional cooperative mutations of SETD2 in human acute leukemia. Nat. Genet. 46, 287\u2013293 (2014).","journal-title":"Nat. Genet."},{"key":"2340_CR115","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1158\/2159-8290.CD-16-0058","volume":"6","author":"L Zhu","year":"2016","unstructured":"Zhu, L. et al. ASH1L links histone H3 lysine 36 dimethylation to MLL leukemia. Cancer Discov. 6, 770\u2013783 (2016).","journal-title":"Cancer Discov."},{"key":"2340_CR116","doi-asserted-by":"publisher","DOI":"10.1172\/JCI153167","volume":"132","author":"J Ren","year":"2022","unstructured":"Ren, J. et al. Histone methyltransferase WHSC1 loss dampens MHC-I antigen presentation pathway to impair IFN-gamma-stimulated antitumor immunity. J. Clin. Investig. 132, e153167 (2022).","journal-title":"J. Clin. Investig."},{"key":"2340_CR117","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.neo.2020.05.002","volume":"22","author":"V Saloura","year":"2020","unstructured":"Saloura, V. et al. WHSC1 monomethylates histone H1 and induces stem-cell like features in squamous cell carcinoma of the head and neck. Neoplasia 22, 283\u2013293 (2020).","journal-title":"Neoplasia"},{"key":"2340_CR118","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1158\/0008-5472.CAN-20-0360","volume":"81","author":"GY Jeong","year":"2021","unstructured":"Jeong, G. Y. et al. NSD3-induced methylation of H3K36 activates NOTCH signaling to drive breast tumor initiation and metastatic progression. Cancer Res. 81, 77\u201390 (2021).","journal-title":"Cancer Res."},{"key":"2340_CR119","doi-asserted-by":"publisher","first-page":"102676","DOI":"10.1016\/j.ebiom.2020.102676","volume":"53","author":"Q Lin","year":"2020","unstructured":"Lin, Q. et al. ZHX2 restricts hepatocellular carcinoma by suppressing stem cell-like traits through KDM2A-mediated H3K36 demethylation. EBioMedicine 53, 102676 (2020).","journal-title":"EBioMedicine"},{"key":"2340_CR120","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/1878-0261.12174","volume":"12","author":"M Staberg","year":"2018","unstructured":"Staberg, M. et al. Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B. Mol. Oncol. 12, 406\u2013420 (2018).","journal-title":"Mol. Oncol."},{"key":"2340_CR121","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ccr.2011.06.010","volume":"20","author":"KM Bernt","year":"2011","unstructured":"Bernt, K. M. et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1. L. Cancer Cell. 20, 66\u201378 (2011).","journal-title":"L. Cancer Cell."},{"key":"2340_CR122","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1347-1","volume":"10","author":"C He","year":"2019","unstructured":"He, C. et al. Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma. Cell Death Dis. 10, 65 (2019).","journal-title":"Cell Death Dis."},{"key":"2340_CR123","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1038\/s41388-024-02998-2","volume":"43","author":"G Wang","year":"2024","unstructured":"Wang, G. et al. The DNA damage-independent ATM signalling maintains CBP\/DOT1L axis in MLL rearranged acute myeloid leukaemia. Oncogene 43, 1900\u20131916 (2024).","journal-title":"Oncogene"},{"key":"2340_CR124","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.celrep.2019.03.047","volume":"27","author":"G MacLeod","year":"2019","unstructured":"MacLeod, G. et al. Genome-wide CRISPR-Cas9 screens expose genetic vulnerabilities and mechanisms of temozolomide sensitivity in glioblastoma stem cells. Cell Rep. 27, 971\u2013986.e979 (2019).","journal-title":"Cell Rep."},{"key":"2340_CR125","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.7150\/jca.90170","volume":"15","author":"P Li","year":"2024","unstructured":"Li, P., Zhang, Z. & Sun, P. DOT1L promotes expression of CD44 through the Wnt\/\u03b2-catenin signaling pathway in early gastric carcinoma. J. Cancer 15, 2276\u20132291 (2024).","journal-title":"J. Cancer"},{"key":"2340_CR126","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1158\/1078-0432.CCR-21-1299","volume":"28","author":"H Kurani","year":"2022","unstructured":"Kurani, H. et al. DOT1L is a novel cancer stem cell target for triple-negative breast cancer. Clin. Cancer Res. 28, 1948\u20131965 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2340_CR127","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8821","volume":"6","author":"MH Cho","year":"2015","unstructured":"Cho, M. H. et al. DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression. Nat. Commun. 6, 7821 (2015).","journal-title":"Nat. Commun."},{"key":"2340_CR128","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.1016\/j.molcel.2021.09.011","volume":"81","author":"J Xu","year":"2021","unstructured":"Xu, J. & Richard, S. Cellular pathways influenced by protein arginine methylation: implications for cancer. Mol. Cell 81, 4357\u20134368 (2021).","journal-title":"Mol. Cell"},{"key":"2340_CR129","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.1016\/j.celrep.2017.11.096","volume":"21","author":"K Chiang","year":"2017","unstructured":"Chiang, K. et al. PRMT5 is a critical regulator of breast cancer stem cell function via histone methylation and FOXP1 expression. Cell Rep. 21, 3498\u20133513 (2017).","journal-title":"Cell Rep."},{"key":"2340_CR130","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10549-017-4597-6","volume":"168","author":"Z Wang","year":"2018","unstructured":"Wang, Z. et al. PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer. Breast Cancer Res. Treat. 168, 531\u2013542 (2018).","journal-title":"Breast Cancer Res. Treat."},{"key":"2340_CR131","doi-asserted-by":"publisher","first-page":"3961","DOI":"10.1172\/JCI85239","volume":"126","author":"Y Jin","year":"2016","unstructured":"Jin, Y. et al. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia. J. Clin. Investig. 126, 3961\u20133980 (2016).","journal-title":"J. Clin. Investig."},{"key":"2340_CR132","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/2159-8290.CD-14-0625","volume":"5","author":"Y Li","year":"2015","unstructured":"Li, Y. et al. PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers. Cancer Discov. 5, 288\u2013303 (2015).","journal-title":"Cancer Discov."},{"key":"2340_CR133","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s43018-024-00736-x","volume":"5","author":"H Dong","year":"2024","unstructured":"Dong, H. et al. Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity. Nat. Cancer 5, 601\u2013624 (2024).","journal-title":"Nat. Cancer"},{"key":"2340_CR134","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.stem.2022.12.003","volume":"30","author":"Y Cheng","year":"2023","unstructured":"Cheng, Y. et al. Decoding m(6)A RNA methylome identifies PRMT6-regulated lipid transport promoting AML stem cell maintenance. Cell Stem Cell 30, 69\u201385.e67 (2023).","journal-title":"Cell Stem Cell"},{"key":"2340_CR135","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.cmet.2022.04.004","volume":"34","author":"C Liu","year":"2022","unstructured":"Liu, C. et al. Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CML. Cell Metab. 34, 818\u2013835.e817 (2022).","journal-title":"Cell Metab."},{"key":"2340_CR136","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/ni.3774","volume":"18","author":"E Dolezal","year":"2017","unstructured":"Dolezal, E. et al. The BTG2-PRMT1 module limits pre-B cell expansion by regulating the CDK4-Cyclin-D3 complex. Nat. Immunol. 18, 911\u2013920 (2017).","journal-title":"Nat. Immunol."},{"key":"2340_CR137","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05389-1","volume":"13","author":"Y Liao","year":"2022","unstructured":"Liao, Y. et al. PRMT3 drives glioblastoma progression by enhancing HIF1A and glycolytic metabolism. Cell Death Dis. 13, 943 (2022).","journal-title":"Cell Death Dis."},{"key":"2340_CR138","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.molcel.2021.01.015","volume":"81","author":"T Huang","year":"2021","unstructured":"Huang, T. et al. PRMT6 methylation of RCC1 regulates mitosis, tumorigenicity, and radiation response of glioblastoma stem cells. Mol. Cell 81, 1276\u20131291.e1279 (2021).","journal-title":"Mol. Cell"},{"key":"2340_CR139","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06968-7","volume":"9","author":"F Dong","year":"2018","unstructured":"Dong, F. et al. PRMT2 links histone H3R8 asymmetric dimethylation to oncogenic activation and tumorigenesis of glioblastoma. Nat. Commun. 9, 4552 (2018).","journal-title":"Nat. Commun."},{"key":"2340_CR140","doi-asserted-by":"publisher","first-page":"e12291","DOI":"10.15252\/emmm.202012291","volume":"12","author":"W Tao","year":"2020","unstructured":"Tao, W. et al. SATB2 drives glioblastoma growth by recruiting CBP to promote FOXM1 expression in glioma stem cells. EMBO Mol. Med. 12, e12291 (2020).","journal-title":"EMBO Mol. Med."},{"key":"2340_CR141","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.18632\/aging.202371","volume":"13","author":"L Hao","year":"2021","unstructured":"Hao, L. et al. ALKBH5-mediated m(6)A demethylation of FOXM1 mRNA promotes progression of uveal melanoma. Aging13, 4045\u20134062 (2021).","journal-title":"Aging"},{"key":"2340_CR142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2018.04.012","volume":"428","author":"Y Jian","year":"2018","unstructured":"Jian, Y. et al. Jade family PHD finger 3 (JADE3) increases cancer stem cell-like properties and tumorigenicity in colon cancer. Cancer Lett. 428, 1\u201311 (2018).","journal-title":"Cancer Lett."},{"key":"2340_CR143","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47680-z","volume":"15","author":"CH Chang","year":"2024","unstructured":"Chang, C. H. et al. The pRb\/RBL2-E2F1\/4-GCN5 axis regulates cancer stem cell formation and G0 phase entry\/exit by paracrine mechanisms. Nat. Commun. 15, 3580 (2024).","journal-title":"Nat. Commun."},{"key":"2340_CR144","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.celrep.2016.09.079","volume":"17","author":"K Tzelepis","year":"2016","unstructured":"Tzelepis, K. et al. A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia. Cell Rep. 17, 1193\u20131205 (2016).","journal-title":"Cell Rep."},{"key":"2340_CR145","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15221-z","volume":"11","author":"L Cabal-Hierro","year":"2020","unstructured":"Cabal-Hierro, L. et al. Chromatin accessibility promotes hematopoietic and leukemia stem cell activity. Nat. Commun. 11, 1406 (2020).","journal-title":"Nat. Commun."},{"key":"2340_CR146","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41586-019-1835-6","volume":"577","author":"L MacPherson","year":"2020","unstructured":"MacPherson, L. et al. HBO1 is required for the maintenance of leukaemia stem cells. Nature 577, 266\u2013270 (2020).","journal-title":"Nature"},{"key":"2340_CR147","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21357-3","volume":"12","author":"J Li","year":"2021","unstructured":"Li, J. et al. ZMYND11-MBTD1 induces leukemogenesis through hijacking NuA4\/TIP60 acetyltransferase complex and a PWWP-mediated chromatin association mechanism. Nat. Commun. 12, 1045 (2021).","journal-title":"Nat. Commun."},{"key":"2340_CR148","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1158\/2159-8290.CD-20-1459","volume":"12","author":"F Yan","year":"2022","unstructured":"Yan, F. et al. KAT6A and ENL form an epigenetic transcriptional control module to drive critical leukemogenic gene-expression programs. Cancer Discov. 12, 792\u2013811 (2022).","journal-title":"Cancer Discov."},{"key":"2340_CR149","doi-asserted-by":"publisher","first-page":"e51754","DOI":"10.7554\/eLife.51754","volume":"9","author":"AF Domingues","year":"2020","unstructured":"Domingues, A. F. et al. Loss of Kat2a enhances transcriptional noise and depletes acute myeloid leukemia stem-like cells. Elife 9, e51754 (2020).","journal-title":"Elife"},{"key":"2340_CR150","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1182\/bloodadvances.2022008787","volume":"7","author":"F Pan","year":"2023","unstructured":"Pan, F. et al. Enhancer remodeling drives MLL oncogene-dependent transcriptional dysregulation in leukemia stem cells. Blood Adv. 7, 2504\u20132519 (2023).","journal-title":"Blood Adv."},{"key":"2340_CR151","doi-asserted-by":"publisher","first-page":"5039","DOI":"10.1158\/0008-5472.CAN-17-0072","volume":"77","author":"KH Song","year":"2017","unstructured":"Song, K. H. et al. HDAC1 upregulation by NANOG promotes multidrug resistance and a stem-like phenotype in immune edited tumor cells. Cancer Res. 77, 5039\u20135053 (2017).","journal-title":"Cancer Res."},{"key":"2340_CR152","doi-asserted-by":"publisher","first-page":"e149232","DOI":"10.1172\/jci.insight.149232","volume":"6","author":"C Lo Cascio","year":"2021","unstructured":"Lo Cascio, C. et al. Nonredundant, isoform-specific roles of HDAC1 in glioma stem cells. JCI Insight 6, e149232 (2021).","journal-title":"JCI Insight"},{"key":"2340_CR153","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40776-y","volume":"14","author":"RK Bahia","year":"2023","unstructured":"Bahia, R. K. et al. Epigenetic and molecular coordination between HDAC2 and SMAD3-SKI regulates essential brain tumour stem cell characteristics. Nat. Commun. 14, 5051 (2023).","journal-title":"Nat. Commun."},{"key":"2340_CR154","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1158\/1535-7163.MCT-20-0037","volume":"19","author":"Q Wang","year":"2020","unstructured":"Wang, Q. et al. A combination of BRD4 and HDAC3 inhibitors synergistically suppresses glioma stem cell growth by blocking GLI1\/IL6\/STAT3 signaling axis. Mol. Cancer Ther. 19, 2542\u20132553 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"2340_CR155","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.canlet.2017.12.005","volume":"415","author":"W Yang","year":"2018","unstructured":"Yang, W. et al. HDAC6 inhibition induces glioma stem cells differentiation and enhances cellular radiation sensitivity through the SHH\/Gli1 signaling pathway. Cancer Lett. 415, 164\u2013176 (2018).","journal-title":"Cancer Lett."},{"key":"2340_CR156","doi-asserted-by":"publisher","first-page":"4932","DOI":"10.1038\/s41388-019-0763-0","volume":"38","author":"T Wang","year":"2019","unstructured":"Wang, T. et al. The inflammatory cytokine IL-6 induces FRA1 deacetylation promoting colorectal cancer stem-like properties. Oncogene 38, 4932\u20134947 (2019).","journal-title":"Oncogene"},{"key":"2340_CR157","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/hep.28690","volume":"64","author":"L Liu","year":"2016","unstructured":"Liu, L. et al. SIRT1-mediated transcriptional regulation of SOX2 is important for self-renewal of liver cancer stem cells. Hepatology 64, 814\u2013827 (2016).","journal-title":"Hepatology"},{"key":"2340_CR158","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1158\/0008-5472.CAN-20-3044","volume":"81","author":"L Bi","year":"2021","unstructured":"Bi, L. et al. HDAC11 regulates glycolysis through the LKB1\/AMPK signaling pathway to maintain hepatocellular carcinoma stemness. Cancer Res. 81, 2015\u20132028 (2021).","journal-title":"Cancer Res."},{"key":"2340_CR159","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.stem.2018.07.018","volume":"23","author":"J Sun","year":"2018","unstructured":"Sun, J. et al. SIRT1 activation disrupts maintenance of myelodysplastic syndrome stem and progenitor cells by restoring TET2 function. Cell Stem Cell 23, 355\u2013369.e359 (2018).","journal-title":"Cell Stem Cell"},{"key":"2340_CR160","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1084\/jem.20121608","volume":"210","author":"SK Singh","year":"2013","unstructured":"Singh, S. K. et al. Sirt1 ablation promotes stress-induced loss of epigenetic and genomic hematopoietic stem and progenitor cell maintenance. J. Exp. Med. 210, 987\u20131001 (2013).","journal-title":"J. Exp. Med."},{"key":"2340_CR161","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.stem.2010.11.013","volume":"7","author":"RU Lukacs","year":"2010","unstructured":"Lukacs, R. U., Memarzadeh, S., Wu, H. & Witte, O. N. Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell 7, 682\u2013693 (2010).","journal-title":"Cell Stem Cell"},{"key":"2340_CR162","doi-asserted-by":"publisher","first-page":"6063","DOI":"10.1158\/0008-5472.CAN-06-0054","volume":"66","author":"S Liu","year":"2006","unstructured":"Liu, S. et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 66, 6063\u20136071 (2006).","journal-title":"Cancer Res."},{"key":"2340_CR163","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nature01572","volume":"423","author":"J Lessard","year":"2003","unstructured":"Lessard, J. & Sauvageau, G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423, 255\u2013260 (2003).","journal-title":"Nature"},{"key":"2340_CR164","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/nm.4415","volume":"23","author":"X Jin","year":"2017","unstructured":"Jin, X. et al. Targeting glioma stem cells through combined BMI1 and EZH2 inhibition. Nat. Med. 23, 1352\u20131361 (2017).","journal-title":"Nat. Med."},{"key":"2340_CR165","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/nm.3418","volume":"20","author":"A Kreso","year":"2014","unstructured":"Kreso, A. et al. Self-renewal as a therapeutic target in human colorectal cancer. Nat. Med. 20, 29\u201336 (2014).","journal-title":"Nat. Med."},{"key":"2340_CR166","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.celrep.2016.06.002","volume":"16","author":"CY Chung","year":"2016","unstructured":"Chung, C. Y. et al. Cbx8 acts non-canonically with Wdr5 to promote mammary tumorigenesis. Cell Rep. 16, 472\u2013486 (2016).","journal-title":"Cell Rep."},{"key":"2340_CR167","doi-asserted-by":"publisher","first-page":"108286","DOI":"10.1016\/j.celrep.2020.108286","volume":"33","author":"I Balakrishnan","year":"2020","unstructured":"Balakrishnan, I. et al. Senescence induced by BMI1 inhibition is a therapeutic vulnerability in H3K27M-mutant DIPG. Cell Rep. 33, 108286 (2020).","journal-title":"Cell Rep."},{"key":"2340_CR168","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/ncb2701","volume":"15","author":"K Klauke","year":"2013","unstructured":"Klauke, K. et al. Polycomb Cbx family members mediate the balance between haematopoietic stem cell self-renewal and differentiation. Nat. Cell Biol. 15, 353\u2013362 (2013).","journal-title":"Nat. Cell Biol."},{"key":"2340_CR169","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1038\/leu.2011.85","volume":"25","author":"J Yuan","year":"2011","unstructured":"Yuan, J. et al. Bmi1 is essential for leukemic reprogramming of myeloid progenitor cells. Leukemia 25, 1335\u20131343 (2011).","journal-title":"Leukemia"},{"key":"2340_CR170","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ccr.2011.09.008","volume":"20","author":"J Tan","year":"2011","unstructured":"Tan, J. et al. CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis. Cancer Cell 20, 563\u2013575 (2011).","journal-title":"Cancer Cell"},{"key":"2340_CR171","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1016\/j.celrep.2019.01.050","volume":"26","author":"J Jung","year":"2019","unstructured":"Jung, J. et al. CBX7 induces self-renewal of human normal and malignant hematopoietic stem and progenitor cells by canonical and non-canonical interactions. Cell Rep. 26, 1906\u20131918.e1908 (2019).","journal-title":"Cell Rep."},{"key":"2340_CR172","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1182\/blood-2017-05-787226","volume":"131","author":"H Shima","year":"2018","unstructured":"Shima, H. et al. Ring1A and Ring1B inhibit expression of Glis2 to maintain murine MOZ-TIF2 AML stem cells. Blood 131, 1833\u20131845 (2018).","journal-title":"Blood"},{"key":"2340_CR173","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1158\/0008-5472.CAN-23-1067","volume":"84","author":"A Mehta","year":"2024","unstructured":"Mehta, A. & Stanger, B. Z. Lineage plasticity: the new cancer hallmark on the block. Cancer Res. 84, 184\u2013191 (2024).","journal-title":"Cancer Res."},{"key":"2340_CR174","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.tcb.2024.01.006","volume":"34","author":"X Qin","year":"2024","unstructured":"Qin, X. & Tape, C. J. Functional analysis of cell plasticity using single-cell technologies. Trends Cell Biol. 34, 854\u2013864 (2024).","journal-title":"Trends Cell Biol."},{"key":"2340_CR175","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1158\/2159-8290.CD-19-0015","volume":"9","author":"S Yuan","year":"2019","unstructured":"Yuan, S., Norgard, R. J. & Stanger, B. Z. Cellular plasticity in cancer. Cancer Discov. 9, 837\u2013851 (2019).","journal-title":"Cancer Discov."},{"key":"2340_CR176","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41591-021-01233-9","volume":"27","author":"I Vitale","year":"2021","unstructured":"Vitale, I., Shema, E., Loi, S. & Galluzzi, L. Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nat. Med. 27, 212\u2013224 (2021).","journal-title":"Nat. Med."},{"key":"2340_CR177","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ccell.2020.12.002","volume":"39","author":"E Dhimolea","year":"2021","unstructured":"Dhimolea, E. et al. An embryonic diapause-like adaptation with suppressed Myc activity enables tumor treatment persistence. Cancer Cell 39, 240\u2013256.e211 (2021).","journal-title":"Cancer Cell"},{"key":"2340_CR178","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41591-019-0750-6","volume":"26","author":"AM Laughney","year":"2020","unstructured":"Laughney, A. M. et al. Regenerative lineages and immune-mediated pruning in lung cancer metastasis. Nat. Med. 26, 259\u2013269 (2020).","journal-title":"Nat. Med."},{"key":"2340_CR179","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.cell.2020.11.018","volume":"184","author":"SK Rehman","year":"2021","unstructured":"Rehman, S. K. et al. Colorectal cancer cells enter a diapause-like DTP state to survive chemotherapy. Cell 184, 226\u2013242.e221 (2021).","journal-title":"Cell"},{"key":"2340_CR180","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nature21713","volume":"543","author":"F de Sousa e Melo","year":"2017","unstructured":"de Sousa e Melo, F. et al. A distinct role for Lgr5(+) stem cells in primary and metastatic colon cancer. Nature 543, 676\u2013680 (2017).","journal-title":"Nature"},{"key":"2340_CR181","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.stem.2020.02.008","volume":"26","author":"A Fumagalli","year":"2020","unstructured":"Fumagalli, A. et al. Plasticity of Lgr5-negative cancer cells drives metastasis in colorectal cancer. Cell Stem Cell 26, 569\u2013578.e567 (2020).","journal-title":"Cell Stem Cell"},{"key":"2340_CR182","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nature22081","volume":"545","author":"M Shimokawa","year":"2017","unstructured":"Shimokawa, M. et al. Visualization and targeting of LGR5(+) human colon cancer stem cells. Nature 545, 187\u2013192 (2017).","journal-title":"Nature"},{"key":"2340_CR183","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/s41586-023-06324-w","volume":"619","author":"NH Juul","year":"2023","unstructured":"Juul, N. H. et al. KRAS(G12D) drives lepidic adenocarcinoma through stem-cell reprogramming. Nature 619, 860\u2013867 (2023).","journal-title":"Nature"},{"key":"2340_CR184","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cell.2012.12.012","volume":"152","author":"S Schwitalla","year":"2013","unstructured":"Schwitalla, S. et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 152, 25\u201338 (2013).","journal-title":"Cell"},{"key":"2340_CR185","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.stem.2014.01.009","volume":"14","author":"M Todaro","year":"2014","unstructured":"Todaro, M. et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell 14, 342\u2013356 (2014).","journal-title":"Cell Stem Cell"},{"key":"2340_CR186","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/ncb2048","volume":"12","author":"L Vermeulen","year":"2010","unstructured":"Vermeulen, L. et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 12, 468\u2013476 (2010).","journal-title":"Nat. Cell Biol."},{"key":"2340_CR187","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09853-z","volume":"10","author":"A Dirkse","year":"2019","unstructured":"Dirkse, A. et al. Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment. Nat. Commun. 10, 1787 (2019).","journal-title":"Nat. Commun."},{"key":"2340_CR188","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1158\/1535-7163.MCT-15-0675","volume":"15","author":"G Lee","year":"2016","unstructured":"Lee, G. et al. Dedifferentiation of glioma cells to glioma stem-like cells by therapeutic stress-induced HIF signaling in the recurrent GBM model. Mol. Cancer Ther. 15, 3064\u20133076 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"2340_CR189","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/stem.1058","volume":"30","author":"C Lagadec","year":"2012","unstructured":"Lagadec, C. et al. Radiation-induced reprogramming of breast cancer cells. Stem Cells 30, 833\u2013844 (2012).","journal-title":"Stem Cells"},{"key":"2340_CR190","first-page":"309","volume":"25","author":"C Wu","year":"2023","unstructured":"Wu, C. et al. Pancreatic cancer cells upregulate LPAR4 in response to isolation stress to promote an ECM-enriched niche and support tumour initiation. Nat. Cell Biol. 25, 309\u2013322 (2023).","journal-title":"Nat. Cell Biol."},{"key":"2340_CR191","doi-asserted-by":"publisher","first-page":"24593","DOI":"10.1073\/pnas.1904091116","volume":"116","author":"A Agarwal","year":"2019","unstructured":"Agarwal, A. et al. Differentiation of leukemic blasts is not completely blocked in acute myeloid leukemia. Proc. Natl. Acad. Sci. USA 116, 24593\u201324599 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2340_CR192","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.stem.2016.11.018","volume":"20","author":"MP Chao","year":"2017","unstructured":"Chao, M. P. et al. Human AML-iPSCs reacquire leukemic properties after differentiation and model clonal variation of disease. Cell Stem Cell 20, 329\u2013344.e327 (2017).","journal-title":"Cell Stem Cell"},{"key":"2340_CR193","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.stem.2019.07.001","volume":"25","author":"MD McKenzie","year":"2019","unstructured":"McKenzie, M. D. et al. Interconversion between tumorigenic and differentiated states in acute myeloid leukemia. Cell Stem Cell 25, 258\u2013272.e259 (2019).","journal-title":"Cell Stem Cell"},{"key":"2340_CR194","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.stem.2017.08.003","volume":"21","author":"C K\u00f6hler","year":"2017","unstructured":"K\u00f6hler, C. et al. Mouse cutaneous melanoma induced by mutant braf arises from expansion and dedifferentiation of mature pigmented melanocytes. Cell Stem Cell 21, 679\u2013693.e676 (2017).","journal-title":"Cell Stem Cell"},{"key":"2340_CR195","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ccr.2010.10.012","volume":"18","author":"E Quintana","year":"2010","unstructured":"Quintana, E. et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18, 510\u2013523 (2010).","journal-title":"Cancer Cell"},{"key":"2340_CR196","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.cell.2010.04.020","volume":"141","author":"A Roesch","year":"2010","unstructured":"Roesch, A. et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141, 583\u2013594 (2010).","journal-title":"Cell"},{"key":"2340_CR197","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature22794","volume":"546","author":"SM Shaffer","year":"2017","unstructured":"Shaffer, S. M. et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature 546, 431\u2013435 (2017).","journal-title":"Nature"},{"key":"2340_CR198","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41434-019-0109-0","volume":"28","author":"W Wang","year":"2021","unstructured":"Wang, W. et al. RETRACTED ARTICLE: inhibition of miR-296-5p protects the heart from cardiac hypertrophy by targeting CACNG6. Gene Ther. 28, 391 (2021).","journal-title":"Gene Ther."},{"key":"2340_CR199","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10681-4","volume":"10","author":"HW Smith","year":"2019","unstructured":"Smith, H. W. et al. An ErbB2\/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis. Nat. Commun. 10, 2901 (2019).","journal-title":"Nat. Commun."},{"key":"2340_CR200","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1016\/j.cell.2021.03.011","volume":"184","author":"W Zhang","year":"2021","unstructured":"Zhang, W. et al. The bone microenvironment invigorates metastatic seeds for further dissemination. Cell 184, 2471\u20132486.e2420 (2021).","journal-title":"Cell"},{"key":"2340_CR201","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.tig.2019.11.004","volume":"36","author":"E Blanco","year":"2020","unstructured":"Blanco, E. et al. The bivalent genome: characterization, structure, and regulation. Trends Genet. 36, 118\u2013131 (2020).","journal-title":"Trends Genet."},{"key":"2340_CR202","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aah4199","volume":"355","author":"SY Ku","year":"2017","unstructured":"Ku, S. Y. et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355, 78\u201383 (2017).","journal-title":"Science"},{"key":"2340_CR203","doi-asserted-by":"publisher","first-page":"e145859","DOI":"10.1172\/JCI145859","volume":"131","author":"YJ Kim","year":"2021","unstructured":"Kim, Y. J. et al. Melanoma dedifferentiation induced by IFN-\u03b3 epigenetic remodeling in response to anti-PD-1 therapy. J. Clin. Invest 131, e145859 (2021).","journal-title":"J. Clin. Invest"},{"key":"2340_CR204","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.stem.2023.05.007","volume":"30","author":"L Beziaud","year":"2023","unstructured":"Beziaud, L. et al. IFNgamma-induced stem-like state of cancer cells as a driver of metastatic progression following immunotherapy. Cell Stem Cell 30, 818\u2013831 e816 (2023).","journal-title":"Cell Stem Cell"},{"key":"2340_CR205","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41590-022-01290-3","volume":"23","author":"M Musella","year":"2022","unstructured":"Musella, M. et al. Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B. Nat. Immunol. 23, 1379\u20131392 (2022).","journal-title":"Nat. Immunol."},{"key":"2340_CR206","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.ccell.2022.11.005","volume":"40","author":"Z Ma","year":"2022","unstructured":"Ma, Z. et al. Interferon-dependent SLC14A1(+) cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancer. Cancer Cell 40, 1550\u20131565.e1557 (2022).","journal-title":"Cancer Cell"},{"key":"2340_CR207","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41568-024-00737-z","volume":"24","author":"M Russo","year":"2024","unstructured":"Russo, M. et al. Cancer drug-tolerant persister cells: from biological questions to clinical opportunities. Nat. Rev. Cancer 24, 694\u2013717 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"2340_CR208","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69\u201380 (2010).","journal-title":"Cell"},{"key":"2340_CR209","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nchembio.2085","volume":"12","author":"M Vinogradova","year":"2016","unstructured":"Vinogradova, M. et al. An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells. Nat. Chem. Biol. 12, 531\u2013538 (2016).","journal-title":"Nat. Chem. Biol."},{"key":"2340_CR210","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ccell.2018.10.014","volume":"34","author":"K Hinohara","year":"2018","unstructured":"Hinohara, K. et al. KDM5 histone demethylase activity links cellular transcriptomic heterogeneity to therapeutic resistance. Cancer Cell 34, 939\u2013953.e939 (2018).","journal-title":"Cancer Cell"},{"key":"2340_CR211","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41588-022-01047-6","volume":"54","author":"J Marsolier","year":"2022","unstructured":"Marsolier, J. et al. H3K27me3 conditions chemotolerance in triple-negative breast cancer. Nat. Genet 54, 459\u2013468 (2022).","journal-title":"Nat. Genet"},{"key":"2340_CR212","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41586-021-03796-6","volume":"596","author":"Y Oren","year":"2021","unstructured":"Oren, Y. et al. Cycling cancer persister cells arise from lineages with distinct programs. Nature 596, 576\u2013582 (2021).","journal-title":"Nature"},{"key":"2340_CR213","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nm.4336","volume":"23","author":"A Giustacchini","year":"2017","unstructured":"Giustacchini, A. et al. Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia. Nat. Med. 23, 692\u2013702 (2017).","journal-title":"Nat. Med."},{"key":"2340_CR214","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.cell.2020.07.017","volume":"182","author":"A Maynard","year":"2020","unstructured":"Maynard, A. et al. Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing. Cell 182, 1232\u20131251.e1222 (2020).","journal-title":"Cell"},{"key":"2340_CR215","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.cell.2018.03.041","volume":"173","author":"C Kim","year":"2018","unstructured":"Kim, C. et al. Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing. Cell 173, 879\u2013893.e813 (2018).","journal-title":"Cell"},{"key":"2340_CR216","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","volume":"20","author":"A Dongre","year":"2019","unstructured":"Dongre, A. & Weinberg, R. A. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat. Rev. Mol. Cell Biol. 20, 69\u201384 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2340_CR217","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41568-021-00332-6","volume":"21","author":"AW Lambert","year":"2021","unstructured":"Lambert, A. W. & Weinberg, R. A. Linking EMT programmes to normal and neoplastic epithelial stem cells. Nat. Rev. Cancer 21, 325\u2013338 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"2340_CR218","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41580-021-00428-9","volume":"22","author":"J Yang","year":"2021","unstructured":"Yang, J. et al. Author correction: guidelines and definitions for research on epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 22, 834 (2021).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2340_CR219","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41580-020-0237-9","volume":"21","author":"J Yang","year":"2020","unstructured":"Yang, J. et al. Guidelines and definitions for research on epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 21, 341\u2013352 (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2340_CR220","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.cell.2012.02.008","volume":"148","author":"W Guo","year":"2012","unstructured":"Guo, W. et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 148, 1015\u20131028 (2012).","journal-title":"Cell"},{"key":"2340_CR221","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","volume":"133","author":"SA Mani","year":"2008","unstructured":"Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704\u2013715 (2008).","journal-title":"Cell"},{"key":"2340_CR222","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41586-023-06682-5","volume":"623","author":"NV Terekhanova","year":"2023","unstructured":"Terekhanova, N. V. et al. Epigenetic regulation during cancer transitions across 11 tumour types. Nature 623, 432\u2013441 (2023).","journal-title":"Nature"},{"key":"2340_CR223","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nature14897","volume":"525","author":"X Ye","year":"2015","unstructured":"Ye, X. et al. Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature 525, 256\u2013260 (2015).","journal-title":"Nature"},{"key":"2340_CR224","doi-asserted-by":"publisher","first-page":"4770","DOI":"10.1073\/pnas.1914937117","volume":"117","author":"H Jiang","year":"2020","unstructured":"Jiang, H. et al. Chromatin remodeling factor ARID2 suppresses hepatocellular carcinoma metastasis via DNMT1-Snail axis. Proc. Natl. Acad. Sci. USA 117, 4770\u20134780 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2340_CR225","doi-asserted-by":"publisher","first-page":"5551","DOI":"10.1038\/onc.2017.159","volume":"36","author":"C Pistore","year":"2017","unstructured":"Pistore, C. et al. DNA methylation variations are required for epithelial-to-mesenchymal transition induced by cancer-associated fibroblasts in prostate cancer cells. Oncogene 36, 5551\u20135566 (2017).","journal-title":"Oncogene"},{"key":"2340_CR226","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.celrep.2019.10.004","volume":"29","author":"Y Zeng","year":"2019","unstructured":"Zeng, Y. et al. Regulation of EZH2 by SMYD2-mediated lysine methylation is implicated in tumorigenesis. Cell Rep. 29, 1482\u20131498.e1484 (2019).","journal-title":"Cell Rep."},{"key":"2340_CR227","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/onc.2016.260","volume":"36","author":"C Battistelli","year":"2017","unstructured":"Battistelli, C. et al. The Snail repressor recruits EZH2 to specific genomic sites through the enrollment of the lncRNA HOTAIR in epithelial-to-mesenchymal transition. Oncogene 36, 942\u2013955 (2017).","journal-title":"Oncogene"},{"key":"2340_CR228","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1111\/cas.14173","volume":"110","author":"Y Hu","year":"2019","unstructured":"Hu, Y. et al. G9a and histone deacetylases are crucial for Snail2-mediated E-cadherin repression and metastasis in hepatocellular carcinoma. Cancer Sci. 110, 3442\u20133452 (2019).","journal-title":"Cancer Sci."},{"key":"2340_CR229","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-019-1216-y","volume":"21","author":"S Punzi","year":"2019","unstructured":"Punzi, S. et al. WDR5 inhibition halts metastasis dissemination by repressing the mesenchymal phenotype of breast cancer cells. Breast Cancer Res. 21, 123 (2019).","journal-title":"Breast Cancer Res."},{"key":"2340_CR230","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ccell.2015.12.006","volume":"29","author":"M Serresi","year":"2016","unstructured":"Serresi, M. et al. Polycomb repressive complex 2 is a barrier to KRAS-driven inflammation and epithelial-mesenchymal transition in non-small-cell lung cancer. Cancer Cell 29, 17\u201331 (2016).","journal-title":"Cancer Cell"},{"key":"2340_CR231","doi-asserted-by":"publisher","first-page":"100213","DOI":"10.1074\/jbc.RA120.015502","volume":"296","author":"S Wanna-Udom","year":"2021","unstructured":"Wanna-Udom, S. et al. KDM2B is involved in the epigenetic regulation of TGF-\u03b2-induced epithelial-mesenchymal transition in lung and pancreatic cancer cell lines. J. Biol. Chem. 296, 100213 (2021).","journal-title":"J. Biol. Chem."},{"key":"2340_CR232","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.cell.2013.06.005","volume":"154","author":"CL Chaffer","year":"2013","unstructured":"Chaffer, C. L. et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 154, 61\u201374 (2013).","journal-title":"Cell"},{"key":"2340_CR233","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1038\/s41556-022-00971-3","volume":"24","author":"SK Sahu","year":"2022","unstructured":"Sahu, S. K. et al. A complex epigenome-splicing crosstalk governs epithelial-to-mesenchymal transition in metastasis and brain development. Nat. Cell Biol. 24, 1265\u20131277 (2022).","journal-title":"Nat. Cell Biol."},{"key":"2340_CR234","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41586-024-07328-w","volume":"629","author":"V Parreno","year":"2024","unstructured":"Parreno, V. et al. Transient loss of polycomb components induces an epigenetic cancer fate. Nature 629, 688\u2013696 (2024).","journal-title":"Nature"},{"key":"2340_CR235","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41576-023-00601-0","volume":"24","author":"J Haerinck","year":"2023","unstructured":"Haerinck, J., Goossens, S. & Berx, G. The epithelial-mesenchymal plasticity landscape: principles of design and mechanisms of regulation. Nat. Rev. Genet. 24, 590\u2013609 (2023).","journal-title":"Nat. Rev. Genet."},{"key":"2340_CR236","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1016\/j.devcel.2021.11.006","volume":"56","author":"F L\u00fc\u00f6nd","year":"2021","unstructured":"L\u00fc\u00f6nd, F. et al. Distinct contributions of partial and full EMT to breast cancer malignancy. Dev. Cell 56, 3203\u20133221.e3211 (2021).","journal-title":"Dev. Cell"},{"key":"2340_CR237","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41586-018-0040-3","volume":"556","author":"I Pastushenko","year":"2018","unstructured":"Pastushenko, I. et al. Identification of the tumour transition states occurring during EMT. Nature 556, 463\u2013468 (2018).","journal-title":"Nature"},{"key":"2340_CR238","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.ccell.2021.05.005","volume":"39","author":"KP Simeonov","year":"2021","unstructured":"Simeonov, K. P. et al. Single-cell lineage tracing of metastatic cancer reveals selection of hybrid EMT states. Cancer Cell 39, 1150\u20131162.e1159 (2021).","journal-title":"Cancer Cell"},{"key":"2340_CR239","doi-asserted-by":"publisher","first-page":"E2337","DOI":"10.1073\/pnas.1618298114","volume":"114","author":"B Bierie","year":"2017","unstructured":"Bierie, B. et al. Integrin-\u03b24 identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells. Proc. Natl. Acad. Sci. USA 114, E2337\u2013e2346 (2017).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2340_CR240","doi-asserted-by":"publisher","first-page":"7353","DOI":"10.1073\/pnas.1812876116","volume":"116","author":"C Kr\u00f6ger","year":"2019","unstructured":"Kr\u00f6ger, C. et al. Acquisition of a hybrid E\/M state is essential for tumorigenicity of basal breast cancer cells. Proc. Natl. Acad. Sci. USA 116, 7353\u20137362 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2340_CR241","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41586-020-03046-1","volume":"589","author":"I Pastushenko","year":"2021","unstructured":"Pastushenko, I. et al. Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis. Nature 589, 448\u2013455 (2021).","journal-title":"Nature"},{"key":"2340_CR242","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1038\/s41388-023-02749-9","volume":"42","author":"RA Sample","year":"2023","unstructured":"Sample, R. A., Nogueira, M. F., Mitra, R. D. & Puram, S. V. Epigenetic regulation of hybrid epithelial-mesenchymal cell states in cancer. Oncogene 42, 2237\u20132248 (2023).","journal-title":"Oncogene"},{"key":"2340_CR243","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s43018-023-00716-7","volume":"5","author":"M Jakab","year":"2024","unstructured":"Jakab, M. et al. Lung endothelium exploits susceptible tumor cell states to instruct metastatic latency. Nat. Cancer 5, 716\u2013730 (2024).","journal-title":"Nat. Cancer"},{"key":"2340_CR244","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07011-y","volume":"15","author":"A Gallardo","year":"2024","unstructured":"Gallardo, A. et al. EZH2 represses mesenchymal genes and upholds the epithelial state of breast carcinoma cells. Cell Death Dis. 15, 609 (2024).","journal-title":"Cell Death Dis."},{"key":"2340_CR245","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1038\/s41388-022-02375-x","volume":"41","author":"A Gallardo","year":"2022","unstructured":"Gallardo, A. et al. EZH2 endorses cell plasticity to non-small cell lung cancer cells facilitating mesenchymal to epithelial transition and tumour colonization. Oncogene 41, 3611\u20133624 (2022).","journal-title":"Oncogene"},{"key":"2340_CR246","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/s41556-022-00877-0","volume":"24","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Genome-wide CRISPR screen identifies PRC2 and KMT2D-COMPASS as regulators of distinct EMT trajectories that contribute differentially to metastasis. Nat. Cell Biol. 24, 554\u2013564 (2022).","journal-title":"Nat. Cell Biol."},{"key":"2340_CR247","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/hep.29778","volume":"68","author":"H Zheng","year":"2018","unstructured":"Zheng, H. et al. Single-cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma. Hepatology 68, 127\u2013140 (2018).","journal-title":"Hepatology"},{"key":"2340_CR248","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/gutjnl-2021-324321","volume":"71","author":"L Zhou","year":"2022","unstructured":"Zhou, L. et al. Lineage tracing and single-cell analysis reveal proliferative Prom1+ tumour-propagating cells and their dynamic cellular transition during liver cancer progression. Gut 71, 1656\u20131668 (2022).","journal-title":"Gut"},{"key":"2340_CR249","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.stemcr.2013.11.009","volume":"2","author":"S Liu","year":"2014","unstructured":"Liu, S. et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Rep. 2, 78\u201391 (2014).","journal-title":"Stem Cell Rep."},{"key":"2340_CR250","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.64090","volume":"10","author":"P Guilhamon","year":"2021","unstructured":"Guilhamon, P. et al. Single-cell chromatin accessibility profiling of glioblastoma identifies an invasive cancer stem cell population associated with lower survival. Elife 10, e64090 (2021).","journal-title":"Elife"},{"key":"2340_CR251","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","volume":"344","author":"AP Patel","year":"2014","unstructured":"Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396\u20131401 (2014).","journal-title":"Science"},{"key":"2340_CR252","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1016\/j.cell.2021.03.023","volume":"184","author":"E Gangoso","year":"2021","unstructured":"Gangoso, E. et al. Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion. Cell 184, 2454\u20132470.e2426 (2021).","journal-title":"Cell"},{"key":"2340_CR253","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33943-0","volume":"13","author":"SD Muthukrishnan","year":"2022","unstructured":"Muthukrishnan, S. D. et al. P300 promotes tumor recurrence by regulating radiation-induced conversion of glioma stem cells to vascular-like cells. Nat. Commun. 13, 6202 (2022).","journal-title":"Nat. Commun."},{"key":"2340_CR254","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41588-022-01088-x","volume":"54","author":"WR Becker","year":"2022","unstructured":"Becker, W. R. et al. Single-cell analyses define a continuum of cell state and composition changes in the malignant transformation of polyps to colorectal cancer. Nat. Genet 54, 985\u2013995 (2022).","journal-title":"Nat. Genet"},{"key":"2340_CR255","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/s41556-018-0179-z","volume":"20","author":"KJ Lenos","year":"2018","unstructured":"Lenos, K. J. et al. Stem cell functionality is microenvironmentally defined during tumour expansion and therapy response in colon cancer. Nat. Cell Biol. 20, 1193\u20131202 (2018).","journal-title":"Nat. Cell Biol."},{"key":"2340_CR256","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/s43018-022-00402-0","volume":"3","author":"A \u00c1lvarez-Varela","year":"2022","unstructured":"\u00c1lvarez-Varela, A. et al. Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy. Nat. Cancer 3, 1052\u20131070 (2022).","journal-title":"Nat. Cancer"},{"key":"2340_CR257","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.canlet.2021.11.032","volume":"526","author":"K Kamachi","year":"2022","unstructured":"Kamachi, K. et al. Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia. Cancer Lett. 526, 273\u2013283 (2022).","journal-title":"Cancer Lett."},{"key":"2340_CR258","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1172\/JCI78789","volume":"125","author":"Y Saunthararajah","year":"2015","unstructured":"Saunthararajah, Y. et al. Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes. J. Clin. Investig. 125, 1043\u20131055 (2015).","journal-title":"J. Clin. Investig."},{"key":"2340_CR259","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1158\/0008-5472.CAN-15-2249","volume":"76","author":"R Pathania","year":"2016","unstructured":"Pathania, R. et al. Combined inhibition of DNMT and HDAC blocks the tumorigenicity of cancer stem-like cells and attenuates mammary tumor growth. Cancer Res. 76, 3224\u20133235 (2016).","journal-title":"Cancer Res."},{"key":"2340_CR260","doi-asserted-by":"publisher","first-page":"6653","DOI":"10.1158\/1078-0432.CCR-21-2139","volume":"27","author":"PD Zavras","year":"2021","unstructured":"Zavras, P. D. et al. Clinical trials assessing hypomethylating agents combined with other therapies: causes for failure and potential solutions. Clin. Cancer Res. 27, 6653\u20136661 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2340_CR261","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22874-x","volume":"12","author":"F Wang","year":"2021","unstructured":"Wang, F. et al. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nat. Commun. 12, 2607 (2021).","journal-title":"Nat. Commun."},{"key":"2340_CR262","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41588-017-0001-z","volume":"50","author":"S Turcan","year":"2018","unstructured":"Turcan, S. et al. Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence. Nat. Genet. 50, 62\u201372 (2018).","journal-title":"Nat. Genet."},{"key":"2340_CR263","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1038\/nm.4210","volume":"22","author":"OA Guryanova","year":"2016","unstructured":"Guryanova, O. A. et al. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nat. Med. 22, 1488\u20131495 (2016).","journal-title":"Nat. Med."},{"key":"2340_CR264","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s41556-023-01109-9","volume":"25","author":"R Ramabadran","year":"2023","unstructured":"Ramabadran, R. et al. DNMT3A-coordinated splicing governs the stem state switch towards differentiation in embryonic and haematopoietic stem cells. Nat. Cell Biol. 25, 528\u2013539 (2023).","journal-title":"Nat. Cell Biol."},{"key":"2340_CR265","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.233","volume":"10","author":"B Hu","year":"2020","unstructured":"Hu, B. et al. CD13 promotes hepatocellular carcinogenesis and sorafenib resistance by activating HDAC5-LSD1-NF-\u03baB oncogenic signaling. Clin. Transl. Med. 10, e233 (2020).","journal-title":"Clin. Transl. Med."},{"key":"2340_CR266","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.canlet.2017.03.038","volume":"398","author":"M Huang","year":"2017","unstructured":"Huang, M. et al. Targeting KDM1A attenuates Wnt\/\u03b2-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma. Cancer Lett. 398, 12\u201321 (2017).","journal-title":"Cancer Lett."},{"key":"2340_CR267","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41573-024-00920-9","volume":"23","author":"L Galluzzi","year":"2024","unstructured":"Galluzzi, L. et al. Targeting immunogenic cell stress and death for cancer therapy. Nat. Rev. Drug Discov. 23, 445\u2013460 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2340_CR268","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41577-022-00760-x","volume":"23","author":"S Marchi","year":"2023","unstructured":"Marchi, S. et al. Mitochondrial control of inflammation. Nat. Rev. Immunol. 23, 159\u2013173 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"2340_CR269","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.radonc.2017.03.002","volume":"124","author":"CW Luo","year":"2017","unstructured":"Luo, C. W. et al. G9a governs colon cancer stem cell phenotype and chemoradioresistance through PP2A-RPA axis-mediated DNA damage response. Radiother. Oncol. 124, 395\u2013402 (2017).","journal-title":"Radiother. Oncol."},{"key":"2340_CR270","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07077-1","volume":"9","author":"SP Rowbotham","year":"2018","unstructured":"Rowbotham, S. P. et al. H3K9 methyltransferases and demethylases control lung tumor-propagating cells and lung cancer progression. Nat. Commun. 9, 4559 (2018).","journal-title":"Nat. Commun."},{"key":"2340_CR271","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/s41556-018-0233-x","volume":"20","author":"A Avgustinova","year":"2018","unstructured":"Avgustinova, A. et al. Loss of G9a preserves mutation patterns but increases chromatin accessibility, genomic instability and aggressiveness in skin tumours. Nat. Cell Biol. 20, 1400\u20131409 (2018).","journal-title":"Nat. Cell Biol."},{"key":"2340_CR272","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/path.5848","volume":"256","author":"A Nachiyappan","year":"2022","unstructured":"Nachiyappan, A. et al. EHMT1 promotes tumor progression and maintains stemness by regulating ALDH1A1 expression in alveolar rhabdomyosarcoma. J. Pathol. 256, 349\u2013362 (2022).","journal-title":"J. Pathol."},{"key":"2340_CR273","doi-asserted-by":"publisher","first-page":"5900","DOI":"10.1158\/0008-5472.CAN-17-1754","volume":"77","author":"E Metzger","year":"2017","unstructured":"Metzger, E. et al. KDM4 inhibition targets breast cancer stem-like cells. Cancer Res. 77, 5900\u20135912 (2017).","journal-title":"Cancer Res."},{"key":"2340_CR274","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1158\/1078-0432.CCR-17-1533","volume":"24","author":"J Zhou","year":"2018","unstructured":"Zhou, J. et al. PTEN is fundamental for elimination of leukemia stem cells mediated by GSK126 targeting EZH2 in chronic myelogenous leukemia. Clin. Cancer Res. 24, 145\u2013157 (2018).","journal-title":"Clin. Cancer Res."},{"key":"2340_CR275","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nm.4247","volume":"23","author":"S G\u00f6llner","year":"2017","unstructured":"G\u00f6llner, S. et al. Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia. Nat. Med. 23, 69\u201378 (2017).","journal-title":"Nat. Med."},{"key":"2340_CR276","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.ccell.2018.10.008","volume":"34","author":"H Celik","year":"2018","unstructured":"Celik, H. et al. JARID2 functions as a tumor suppressor in myeloid neoplasms by repressing self-renewal in hematopoietic progenitor cells. Cancer Cell 34, 741\u2013756.e748 (2018).","journal-title":"Cancer Cell"},{"key":"2340_CR277","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1038\/s41588-021-00897-w","volume":"53","author":"GL Brien","year":"2021","unstructured":"Brien, G. L. et al. Simultaneous disruption of PRC2 and enhancer function underlies histone H3.3-K27M oncogenic activity in human hindbrain neural stem cells. Nat. Genet. 53, 1221\u20131232 (2021).","journal-title":"Nat. Genet."},{"key":"2340_CR278","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/leu.2013.288","volume":"28","author":"K Lund","year":"2014","unstructured":"Lund, K., Adams, P. D. & Copland, M. EZH2 in normal and malignant hematopoiesis. Leukemia 28, 44\u201349 (2014).","journal-title":"Leukemia"},{"key":"2340_CR279","doi-asserted-by":"publisher","first-page":"6075","DOI":"10.1073\/pnas.1814634116","volume":"116","author":"M Wassef","year":"2019","unstructured":"Wassef, M. et al. EZH1\/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer. Proc. Natl. Acad. Sci. USA 116, 6075\u20136080 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2340_CR280","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.150","volume":"6","author":"YW Liu","year":"2015","unstructured":"Liu, Y. W. et al. LincHOTAIR epigenetically silences miR34a by binding to PRC2 to promote the epithelial-to-mesenchymal transition in human gastric cancer. Cell Death Dis. 6, e1802 (2015).","journal-title":"Cell Death Dis."},{"key":"2340_CR281","doi-asserted-by":"publisher","first-page":"e202311021","DOI":"10.1083\/jcb.202311021","volume":"223","author":"TH Shi","year":"2024","unstructured":"Shi, T. H., Sugishita, H. & Gotoh, Y. Crosstalk within and beyond the polycomb repressive system. J. Cell Biol. 223, e202311021 (2024).","journal-title":"J. Cell Biol."},{"key":"2340_CR282","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1111\/cas.14840","volume":"112","author":"J Huang","year":"2021","unstructured":"Huang, J. et al. The noncanonical role of EZH2 in cancer. Cancer Sci. 112, 1376\u20131382 (2021).","journal-title":"Cancer Sci."},{"key":"2340_CR283","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/s41588-018-0114-z","volume":"50","author":"M Gozdecka","year":"2018","unstructured":"Gozdecka, M. et al. UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs. Nat. Genet. 50, 883\u2013894 (2018).","journal-title":"Nat. Genet."},{"key":"2340_CR284","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41375-019-0497-6","volume":"34","author":"SM Stief","year":"2020","unstructured":"Stief, S. M. et al. Loss of KDM6A confers drug resistance in acute myeloid leukemia. Leukemia 34, 50\u201362 (2020).","journal-title":"Leukemia"},{"key":"2340_CR285","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1128\/MCB.01463-12","volume":"33","author":"LL Ho","year":"2013","unstructured":"Ho, L. L. et al. DOT1L-mediated H3K79 methylation in chromatin is dispensable for Wnt pathway-specific and other intestinal epithelial functions. Mol. Cell Biol. 33, 1735\u20131745 (2013).","journal-title":"Mol. Cell Biol."},{"key":"2340_CR286","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.1182\/blood-2010-10-312736","volume":"117","author":"J He","year":"2011","unstructured":"He, J., Nguyen, A. T. & Zhang, Y. KDM2b\/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia. Blood 117, 3869\u20133880 (2011).","journal-title":"Blood"},{"key":"2340_CR287","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/s41589-022-01024-4","volume":"18","author":"Q Wu","year":"2022","unstructured":"Wu, Q. et al. PRMT inhibition induces a viral mimicry response in triple-negative breast cancer. Nat. Chem. Biol. 18, 821\u2013830 (2022).","journal-title":"Nat. Chem. Biol."},{"key":"2340_CR288","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21204-5","volume":"12","author":"P Sachamitr","year":"2021","unstructured":"Sachamitr, P. et al. PRMT5 inhibition disrupts splicing and stemness in glioblastoma. Nat. Commun. 12, 979 (2021).","journal-title":"Nat. Commun."},{"key":"2340_CR289","doi-asserted-by":"publisher","first-page":"eadn1285","DOI":"10.1126\/scitranslmed.adn1285","volume":"16","author":"V Rondeau","year":"2024","unstructured":"Rondeau, V. et al. Spermidine metabolism regulates leukemia stem and progenitor cell function through KAT7 expression in patient-derived mouse models. Sci. Transl. Med 16, eadn1285 (2024).","journal-title":"Sci. Transl. Med"},{"key":"2340_CR290","doi-asserted-by":"publisher","first-page":"eadl1584","DOI":"10.1126\/sciadv.adl1584","volume":"10","author":"MU Nguyen","year":"2024","unstructured":"Nguyen, M. U. et al. KAT2A and KAT2B prevent double-stranded RNA accumulation and interferon signaling to maintain intestinal stem cell renewal. Sci. Adv. 10, eadl1584 (2024).","journal-title":"Sci. Adv."},{"key":"2340_CR291","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.stem.2017.02.003","volume":"20","author":"D Chen","year":"2017","unstructured":"Chen, D. et al. Targeting BMI1(+) cancer stem cells overcomes chemoresistance and inhibits metastases in squamous cell carcinoma. Cell Stem Cell 20, 621\u2013634.e626 (2017).","journal-title":"Cell Stem Cell"},{"key":"2340_CR292","doi-asserted-by":"publisher","first-page":"6176","DOI":"10.1158\/1078-0432.CCR-15-3107","volume":"22","author":"N Bansal","year":"2016","unstructured":"Bansal, N. et al. BMI-1 targeting interferes with patient-derived tumor-initiating cell survival and tumor growth in prostate cancer. Clin. Cancer Res. 22, 6176\u20136191 (2016).","journal-title":"Clin. Cancer Res."},{"key":"2340_CR293","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41568-021-00357-x","volume":"21","author":"S Zhao","year":"2021","unstructured":"Zhao, S., Allis, C. D. & Wang, G. G. The language of chromatin modification in human cancers. Nat. Rev. Cancer 21, 413\u2013430 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"2340_CR294","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nrm.2017.26","volume":"18","author":"CR Clapier","year":"2017","unstructured":"Clapier, C. R., Iwasa, J., Cairns, B. R. & Peterson, C. L. Mechanisms of action and regulation of ATP-dependent chromatin-remodelling complexes. Nat. Rev. Mol. Cell Biol. 18, 407\u2013422 (2017).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2340_CR295","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41576-023-00645-2","volume":"25","author":"S Delaunay","year":"2024","unstructured":"Delaunay, S., Helm, M. & Frye, M. RNA modifications in physiology and disease: towards clinical applications. Nat. Rev. Genet. 25, 104\u2013122 (2024).","journal-title":"Nat. Rev. Genet."},{"key":"2340_CR296","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.tig.2021.06.014","volume":"38","author":"RL Kan","year":"2022","unstructured":"Kan, R. L., Chen, J. & Sallam, T. Crosstalk between epitranscriptomic and epigenetic mechanisms in gene regulation. Trends Genet. 38, 182\u2013193 (2022).","journal-title":"Trends Genet."},{"key":"2340_CR297","doi-asserted-by":"publisher","first-page":"102270","DOI":"10.1016\/j.gde.2024.102270","volume":"89","author":"A Louwagie","year":"2024","unstructured":"Louwagie, A. & Vu, L. P. Emerging interactions between RNA methylation and chromatin architecture. Curr. Opin. Genet. Dev. 89, 102270 (2024).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"2340_CR298","doi-asserted-by":"publisher","first-page":"102205","DOI":"10.1016\/j.gde.2024.102205","volume":"86","author":"Y Wang","year":"2024","unstructured":"Wang, Y., Huang, H., Chen, J. & Weng, H. Crosstalk between histone\/DNA modifications and RNA N(6)-methyladenosine modification. Curr. Opin. Genet. Dev. 86, 102205 (2024).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"2340_CR299","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01220-7","volume":"19","author":"X Chen","year":"2020","unstructured":"Chen, X. et al. METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer. Mol. Cancer 19, 106 (2020).","journal-title":"Mol. Cancer"},{"key":"2340_CR300","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09712-x","volume":"10","author":"J Zhang","year":"2019","unstructured":"Zhang, J. et al. Excessive miR-25-3p maturation via N(6)-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression. Nat. Commun. 10, 1858 (2019).","journal-title":"Nat. Commun."},{"key":"2340_CR301","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/nature08975","volume":"464","author":"RA Gupta","year":"2010","unstructured":"Gupta, R. A. et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464, 1071\u20131076 (2010).","journal-title":"Nature"},{"key":"2340_CR302","doi-asserted-by":"publisher","first-page":"6299","DOI":"10.1158\/0008-5472.CAN-16-0356","volume":"76","author":"M Sun","year":"2016","unstructured":"Sun, M. et al. LncRNA HOXA11-AS promotes proliferation and invasion of gastric cancer by scaffolding the chromatin modification factors PRC2, LSD1, and DNMT1. Cancer Res. 76, 6299\u20136310 (2016).","journal-title":"Cancer Res."},{"key":"2340_CR303","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/cdd.2016.95","volume":"24","author":"Z Li","year":"2017","unstructured":"Li, Z. et al. The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer. Cell Death Differ. 24, 59\u201371 (2017).","journal-title":"Cell Death Differ."},{"key":"2340_CR304","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09784-9","volume":"10","author":"J Luo","year":"2019","unstructured":"Luo, J. et al. LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2\/STAT3 signaling. Nat. Commun. 10, 2571 (2019).","journal-title":"Nat. Commun."},{"key":"2340_CR305","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04386-0","volume":"12","author":"K Guo","year":"2021","unstructured":"Guo, K. et al. LncRNA-MIAT promotes thyroid cancer progression and function as ceRNA to target EZH2 by sponging miR-150-5p. Cell Death Dis. 12, 1097 (2021).","journal-title":"Cell Death Dis."},{"key":"2340_CR306","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0680-1","volume":"16","author":"H Wang","year":"2017","unstructured":"Wang, H. et al. STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4. Mol. Cancer 16, 136 (2017).","journal-title":"Mol. Cancer"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02340-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02340-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02340-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T11:24:56Z","timestamp":1757330696000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02340-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":306,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2340"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02340-6","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ME is\/has been holding research contracts with Ferrer International and Incyte and receives personal fees from Quimatryx (outside the scope of this work). LG is\/has been holding research contracts with Lytix Biopharma, Promontory, and Onxeo; has received consulting\/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Imvax, Sotio, Promontory, Noxopharm, EduCom, and the Luke Heller TECPR2 Foundation; and holds Promontory stock options. The other authors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"243"}}